Cargando…

Pancreatic Cancer: Beyond Brca Mutations

Pancreatic cancer is the fourth-leading cause of cancer-related deaths worldwide. The outcomes in patients with pancreatic cancer remain unsatisfactory. In the current review, we summarize the genetic and epigenetic architecture of metastatic pancreatic cancer beyond the BRCA mutations, focusing on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricci, Vincenzo, Fabozzi, Teresa, Bareschino, Maria Anna, Barletta, Emiddio, Germano, Domenico, Paciolla, Immacolata, Tinessa, Vincenza, Grimaldi, Antonio Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787452/ https://www.ncbi.nlm.nih.gov/pubmed/36556296 http://dx.doi.org/10.3390/jpm12122076

Ejemplares similares

A Fatal Brain Stroke in Patient with Advanced Breast Cancer Treated with Bevacizumab: A Case Report
por: Domenico, Germano, et al.
Publicado: (2010)

Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance
por: Martínez-Galán, Joaquina, et al.
Publicado: (2021)

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
por: Hu, Yunlong, et al.
Publicado: (2020)

Pancreatic Cancer: BRCA Targeted Therapy and Beyond
por: Keane, Fergus, et al.
Publicado: (2023)

Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
por: Germani, Aldo, et al.
Publicado: (2020)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations
por: Chahla, Elie, et al.
Publicado: (2016)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
por: Mai, Phuong L., et al.
Publicado: (2009)

BRCA mutated pancreatic cancer: A change is coming
por: Rosen, Michael N, et al.
Publicado: (2021)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Investigating men’s motivations to engage in genetic screening for BRCA1 and BRCA2 mutations
por: Annoni, Anna Maria, et al.
Publicado: (2022)

Five Italian Families with Two Mutations in BRCA Genes
por: Vietri, Maria Teresa, et al.
Publicado: (2020)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients
por: Dalmasso, Bruna, et al.
Publicado: (2022)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers
por: Rizzolo, Piera, et al.
Publicado: (2018)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
por: Golan, T, et al.
Publicado: (2014)

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
por: Devico Marciano, Naomie, et al.
Publicado: (2022)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study
por: Kowalik, Artur, et al.
Publicado: (2018)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer
por: Vietri, Maria Teresa, et al.
Publicado: (2021)

Pancreatic Cancer Research beyond DNA Mutations
por: Sato, Hiromichi, et al.
Publicado: (2022)

Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
por: Lowery, Maeve A.
Publicado: (2019)

Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia
por: Briceño-Balcázar, Ignacio, et al.
Publicado: (2017)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population
por: Palomba, Grazia, et al.
Publicado: (2009)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
por: Takeuchi, Shoko, et al.
Publicado: (2018)

BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer
por: Kondo, Tomohiro, et al.
Publicado: (2020)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
por: Schettino, Clorinda, et al.
Publicado: (2008)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8subqgtrtkbpt3g2o8n3cduha2